Takeda Recognized as a DX Stocks 2026 | Takeda Pharmaceuticals

OSAKA, Japan and CAMBRIDGE, Massachusetts, April 10, 2026 – Takeda (TSE:4502/NYSE:TAK) today announced that it has been selected as a Digital Transformation (DX) Stocks 2026 under the DX Stocks program jointly organized by Japan’s Ministry of Economy, Trade and Industry (METI), the Tokyo Stock Exchange (TSE), and the Information-technology Promotion Agency (IPA).
The DX Stocks program recognizes listed companies that have established internal frameworks to promote digital transformation that contributes to enhanced corporate value and that demonstrate outstanding results through effective use of digital technologies. By highlighting role model companies, the program aims to encourage management-level mindset transformation, foster broader recognition among diverse stakeholders, and further accelerate the adoption of DX initiatives across industries.

The comprehensive evaluation comments from the evaluation panel for Takeda’s DX Stocks 2026 selection are as follows:
“Takeda is strategically promoting enterprise-wide digital transformation through initiatives such as strengthening engagement with healthcare professionals and reforming its supply chain. By leveraging advanced technologies including AI, IoT, and blockchain, it achieves both improved customer and employee experiences, while reducing environmental impact. Through value creation enabled by collaboration between people and digital technologies, and by accelerating improvement cycles through co-creation between digital teams and manufacturing and process experts, the company has realized a highly executable and sustainable DX model. These initiatives are highly commendable as leading-edge practices within the industry.”

“Takeda is advancing DX globally and has achieved sophisticated utilization of data, digital technologies, and AI across many areas including drug discovery, manufacturing, and commercialization. In addition to enhancing internal talent development, the company has strategically strengthened talent acquisition under a Build-Operate-Transform-Transfer (BOTT) model, collaborating closely with external partners to recruit and develop highly specialized professionals. As a result, Takeda has successfully attracted a wide range of digital and data experts.
Under strong executive commitment and a clearly defined DX strategy, highly skilled talent is leveraging robust system foundations across the company. Further advancement in the use of data, digital technologies, and AI is expected going forward.”

Takeda is leveraging AI across its entire value chain to transform operations and improve productivity. These efforts include optimizing manufacturing processes, supporting diagnostics, delivering valuable information to healthcare professionals, and accelerating research and development of innovative medicines—enabling Takeda to better serve patients through its daily operations.

In research and development, Takeda is accelerating the identification of candidate molecules using AI. In manufacturing, the company is improving productivity through process automation. In collaboration with healthcare professionals and other stakeholders, Takeda is focusing on a Go-to-Market model that delivers optimal information and services. By utilizing data, digital, and technology capabilities, Takeda aims not only to enhance the customer experience for healthcare professionals, but also to improve the employee experience. From a talent development perspective, Takeda is promoting AI utilization globally and is actively investing in DX talent development, with more than 20,000 employees engaged in digital learning initiatives worldwide.

Takeda’s Data, Digital & Technology initiatives are built on the following four key pillars:

1. Data, Digital & Technology Strategy Supporting the Corporate Vision Takeda enhances productivity and drives innovation across the enterprise by leveraging advanced technologies, including AI. Its DD&T strategy supports growth of Takeda’s medicines and advancement of its R&D pipeline, spanning the entire value chain—from research and development to manufacturing, commercialization, and patient support.
2. Priority Area: Value Creation and Governance Enhancement through AI Takeda utilizes AI across the entire value chain to transform operations and improve productivity, including manufacturing optimization, diagnostic support, optimal information delivery to healthcare professionals, and innovative R&D activities. In parallel, grounded in the principles of Responsible AI, including Human in the Loop, Takeda emphasizes high ethical standards and trustworthiness required in the healthcare and pharmaceutical sectors, ensuring a balance between value creation and risk management without over-reliance on AI-driven decision-making.
3. Business Model Transformation through DX
   • Factory of the Future Takeda is advancing Factory of the Future, its global manufacturing DX program, as part of its global manufacturing network spanning more than 25 sites worldwide. Under this program, global sites pursue transformation based on roadmaps tailored to product characteristics, focusing on three key dimensions: digital education, automation, and productivity improvement.
   • Enhancing Experiences through the Go-to-Market Model In Japan, Takeda is advancing initiatives that leverage data, digital technologies, and technology capabilities to deliver optimal information and services to healthcare professionals, with the goal of providing better healthcare outcomes for patients.
4. Organizational Enablement for DX: Digital Dexterity that Supports Learning and Growth
   A key driver accelerating DX talent development at Takeda is Digital Dexterity—defined as the capability and willingness to actively embrace and utilize digital technologies to maximize individual and organizational outcomes. Digital Dexterity is positioned as the core foundation of Takeda’s DX talent development efforts.

In addition, Takeda has established Innovation Capability Centers (ICCs) in Slovakia, Mexico, India, as well as in Japan and China. These ICCs serve as strategic hubs for digital innovation and data analytics, functioning as one of the key pillars for strengthening the value chain by developing, delivering, and accelerating the implementation of advanced data and digital solutions.

For more details on Takeda’s DX initiatives, please visit “Takeda’s Digital Initiatives (Japanese)” on our website.

Takeda remains committed to creating value through the power of data and digital technologies, contributing to the health of people around the world and to a brighter, more sustainable future.

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results, except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom.
This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

For press information, please contact:

Tatsuhiro Kanoo
Japan Communications
E-mail: [email protected]